- Home
- NECB vs ACRS Comparison
NECB vs ACRS Comparison
Compare NECB & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NECB | ACRS |
|---|---|---|
| Founded | 1934 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 310.9M | 311.0M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | NECB | ACRS |
|---|---|---|
| Price | $23.28 | $3.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 32.4K | ★ 2.3M |
| Earning Date | 04-20-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.30% | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ 3.25 | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | $9.76 | N/A |
| Revenue Next Year | $11.94 | $4.24 |
| P/E Ratio | $7.17 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.27 | $1.05 |
| 52 Week High | $25.18 | $4.89 |
Technical Indicators
Market Signals| Indicator | NECB | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 44.98 | 54.99 |
| Support Level | $22.87 | $2.76 |
| Resistance Level | $24.50 | $3.78 |
| Average True Range (ATR) | 0.64 | 0.23 |
| MACD | -0.05 | 0.05 |
| Stochastic Oscillator | 38.56 | 68.78 |
Price Performance
Historical ComparisonAbout NECB NorthEast Community Bancorp Inc.
NorthEast Community Bancorp Inc operates as a community-oriented financial institution. It is principally engaged in the business of attracting deposits and investing those funds into mortgage and commercial loans. It conducts activities throughout the Northeastern United States including New York, Massachusetts, New Jersey, and Connecticut. The company offers a comprehensive line of banking products and services, including mobile banking as well as commercial real estate loans, commercial construction financing, lines of credit, and term loans. It also offers investment advisory and financial planning services.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.